
Bio-Rad Laboratories (BIO) Stock Forecast & Price Target
Bio-Rad Laboratories (BIO) Analyst Ratings
Bulls say
Bio-Rad Laboratories is positioned to grow its revenue and earnings at a faster rate than its peers due to expected improvements in end-markets, which could lead to multiple expansions. The company is also set to benefit from ongoing ERP efficiencies that are anticipated to enhance margins, alongside the expected stabilization and growth of its ddPCR and process chromatography segments. With a current valuation of approximately 7x EBITDA and less than 1.5x sales, Bio-Rad presents an attractive entry point for investors as market pressures are expected to subside and growth trends normalize.
Bears say
Bio-Rad Laboratories faces significant risks that contribute to a negative outlook on its stock, primarily stemming from potentially overstated revenue and earnings estimates due to declining demand for its products. The company continues to experience elevated inventories and reduced equipment sales as a result of ongoing supply chain disruptions that were exacerbated during the pandemic. Furthermore, Bio-Rad's exposure to macroeconomic variables, including foreign currency fluctuations and corporate governance risks associated with its majority shareholders, may further complicate its financial trajectory and limit share price growth.
This aggregate rating is based on analysts' research of Bio-Rad Laboratories and is not a guaranteed prediction by Public.com or investment advice.
Bio-Rad Laboratories (BIO) Analyst Forecast & Price Prediction
Start investing in Bio-Rad Laboratories (BIO)
Order type
Buy in
Order amount
Est. shares
0 shares